Table 6. Individual component and the Doylestown algorithm at different time-points before HCC recurrence.
| Time before HCC detected 1 | <1–3 months | 6 months | 9 months | 12 months | P value7 |
|---|---|---|---|---|---|
| Size of tumor at time of detection,cm2 | 1.8 (0.8–5.5) | ||||
| ALK (range,U/L) 3 | 136.9 (34–570) | 111.8 (30–191) | 117.4 (38–205) | 130.1 (38–360) | 0.746 |
| ALT (rangeU/L) 4 | 66.3 (11–309) | 69.8 (16–229) | 54.5 (13–166) | 56.5 (8–268) | 0.8576 |
| AFP (range,ng/mL) 5 | 102 (1–1618) | 23.6 (1.6–84.5) | 15.6 (1.5–64.4) | 14.5 (1.7–92.7) | 0.184 |
| Doylestown algorithm (range) 6 | 0.66 (0.08–1) | 0.62 (0.12–1) | 0.56 (0.12–0.96) | 0.59 (.09–0.97) | 0.5180 |
1) Time before detection of HCC, either <1–3 months prior, 6 months prior, 9 months prior or 12 months prior.
2) Mean size of tumor (in cm) at time of detection with the range provided.
3) Mean level of alkaline phosphatase with the range indicated (in U/L).
4) Mean level of alanine aminotransferase with the range indicated (in U/L).
5) Mean level of alpha-fetoprotein (AFP) with the range indicated (in ng/mL).
6) Mean level of the Doylestown algorithm with the range indicated.
7) Linear mixed effects model.